REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Inclusion Criteria: * Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment. * No NUCALA use in the 6 months prior to enrollment. * Participants with greater than or equal to (≥)60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician. * Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria). * Written informed consent Exclusion Criteria: * Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare) * Participants currently on maintenance OCS or intramuscular corticosteroids. * Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment * Participants participating in an interventional study with a treatment intervention